3
Indication details
- Combined Agent(s)
- Cisplatin and 5-FU ChT
- Control Arm
- Placebo + cisplatin and 5-FU ChT
- Therapeutic Indication
- First-line treatment
- Tumour Type
-
Gastrointestinal Cancers
- Tumour Sub-type
- Oesophageal squamous cell carcinoma
- Tumour Stage
- Locally advanced unresectable or metastatic
- Tumour Sub-Group
- HER2- GEJ (squamous cell)
- Trial Name
- KEYNOTE-590
- NCT Number
- NCT03189719
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval March 2021 Scoring of sub-group analysis
- EMA Approval
- EMA (CHMP) May 2021 EC decision July 2021
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- OS Control
- 9.8 months
- OS Gain
- 2.8 months 12% improvement at 2-years but <10% of patients still on follow up by that time
- OS HR
- 0.72 (0.60-0.88)
Adjustments
- QoL Comment
-
QoL data pending
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
- Comment
-
Scoring of sub-group analysis
EMA (CHMP) May 2021
EC decision July 2021
FDA approval March 2021
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 310
- Scorecard version
- 1
- Issue date
- 20.12.2021